Efficacy and safety of indobufen for prevention and treatment of ischemic cardiovascular and cerebrovascular diseases: a Meta-analysis
10.13699/j.cnki.1001-6821.2017.04.019
- VernacularTitle:吲哚布芬片预防和治疗缺血性心脑血管病变有效性和安全性的Meta分析
- Author:
Xia YANG
1
;
Wei LIU
;
Ken CHEN
;
Shu-Jie DONG
;
Suo-Di ZHAI
Author Information
1. 北京大学第三医院药剂科
- Keywords:
indobufen;
aspirin;
warfarin;
Meta-analysis
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(4):359-362
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of indobufen in the prevention and treatment of ischemic cardiovascular and cerebrovascular diseases or thrombosis.Methods PubMed,EmBase,Cochrane Library,Web of Science,Clinical Trials.gov,CNKI,CBM and WANFANG database were systematically searched until May 2016.All randomized controlled trials (RCTs) of indobufen therapy in patients with ischemic cardiovascular and cerebrovascular disease or thromboembolic disease were selected.Meta-analysis was carried out by using RevMan 5.3 software.The incidence of cardiovascular death,all-cause mortality,stroke,myocardial infarction,embolism,gastrointestinal reactions and bleeding after the treatment were compared and the results were presented with risk ratio (RR) with 95％ confidence interval (CI).Results Nineteen RCTs of 5304 cases were included in this study,including 2668 cases received indobufen (treatment group),other 2636 cases received other drugs (control group).The results of Meta-analysis were as follows.The incidence of bleeding in the indobufen group was lower than that in the warfarin group (P ＜ 0.01).The incidence of bleeding,gastrointestinal reactions and total adverse effects in the indobufen group were lower than those in aspirin group (P ＜ 0.05).The incidence of bleeding and gastrointestinal reactions in the indobufen group were lower than those in the other antiplatelet drugs group (P ＜ 0.05).The incidence of embolism in the indobufen group was significantly lower than that in the placebo or blank group (P ＜ 0.01).Conclusion Although the clinical application of indobufen is relatively few,it is an efficacious and safe choice for ischemic cardiac and cerebral vascular diseases and thrombosis treatment.There should be more large-scale original researches to explore its clinical value.
